Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788528 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects
A Phase 2 study of Obesity, sponsored by Shionogi.
- Completed
- Registry status
- Phase 2
- Development phase
- 766
- Enrollment target
- 20
- Study locations
NCT00788528: Completed Phase 2 study of Obesity, sponsored by Shionogi.
NCT00788528 is a Phase 2 study of Obesity that has completed, run by Shionogi. The registered enrollment target is 766 participants, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00788528, a Phase 2 study of Obesity, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 766 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this open-label extension study is to evaluate the safety and efficacy of velneperit (S-2367) in obese subjects.
Conditions Studied
Interventions
- DRUG S-2367 (velneperit)
Study Locations (20)
Florida
- - Coral Gables
- - Jacksonville
- - Jacksonville
- - Ocala
- - Orlando
- - Stuart
California
- - Carmichael
- - Fountain Valley
- - Sacramento
- - San Diego
- - San Francisco
Alabama
- - Birmingham
- - Huntsville
- - Mobile
Arizona
- - Phoenix
- - Tucson
Connecticut
- - Stamford
- - Waterbury
Arkansas
- - Hot Springs
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 766 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00788528 record still lists
NCT00788528 is an interventional study that assigns participants to a tested intervention. The registered 766 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which S-2367 (velneperit) is the first listed.
NCT00788528 names 20 study sites across 7 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00788528 about?
NCT00788528 is a clinical study titled "Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects". The purpose of this open-label extension study is to evaluate the safety and efficacy of velneperit (S-2367) in obese subjects.
What is the current status of trial NCT00788528?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 766 participants. The study started on 2008-08. Estimated completion is 2010-03.
What conditions does trial NCT00788528 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT00788528?
The interventions under investigation include: S-2367 (velneperit) (DRUG).
Who is sponsoring clinical trial NCT00788528?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00788528 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00788528's enrollment target sits among peer trials
766 97th of 1053 higher than 957 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07195591 · 766 participants · Phase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- NCT03789552 · 765 participants · Phase 3
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05404750 · 768 participants
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia